News >

Bypassing Endocrine Resistance in Advanced HR+ Breast Cancer

Caroline Seymour
Published: Tuesday, Jun 25, 2019

Christopher R. Chitambar, MD, FACP

Christopher R. Chitambar, MD, FACP

Treatment for patients with metastatic hormone receptor (HR)–positive, HER2-negative breast cancer depended on blocking the estrogen receptor (ER), until research showed that cancer proliferation was possible independent of the ER, explained Christopher R. Chitambar, MD, FACP.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Community Practice Connections™: Evolving Applications for PARP Inhibitors in Ovarian Cancer: Building on a Solid FoundationAug 15, 20191.5
Publication Bottom Border
Border Publication